MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial
MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company, has announced a private placement agreement to raise approximately $695,000.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% | |
2. | Renaissance Technologies Jim Simons | 0 | $0 | 0% |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$1.50 | 20,000 | Director | 588,218 | 2025-05-08 | Filing | |
$1.50 | 66,666 | Director | 1,271,726 | 2025-05-08 | Filing | |
$1.50 | 33,333 | Director | 568,218 | 2025-03-03 | Filing | |
$1.50 | 25,000 | Director | 1,205,060 | 2025-03-03 | Filing | |
$1.50 | 50,000 | Director | 1,180,060 | 2025-02-24 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 650,256 | $994,892 | 0% | |
2. | 237,356 | $363,156 | 0.19% | |
3. | 214,437 | $328,199 | 0% | |
4. | 84,083 | $128,646 | 0% | |
5. | 68,248 | $104,419 | 0.03% |